Developing treatments for chronic diseases
 
family

We Develop Treatments For Chronic Diseases

TheraVasc, Inc. is a privately held, Ohio Based pharmaceutical company which is developing treatments for various chronic medical diseases using an oral formulation of sodium nitrite. Initial studies were done on patients with poor blood flow to the extremities, such as those suffering from peripheral artery disease (PAD).  In the U.S., 16 - 19 million people suffer from PAD but no effective treatments are currently available.
Learn more about us
family

TV1001SR is Being Developed to Treat Diabetic Neuropathy

We are developing a new drug, TV1001SR, to aid in the treatment of pain associated with diabetic neuropathy. With the incidence of diabetes steadily increasing and more people suffering from the symptoms of diabetic neuropathy, our research and development of this new drug may help reduce pain.
Learn more TV1001SR and Diabetic Neuropathy
family

TV1001SR and the Treatment of Peripheral Artery Disease (PAD)

Peripheral artery disease (PAD) is a chronic disorder associated with reduced blood flow to the lower extremities affecting between 12-14 million people in the U.S. We are developing TV1001SR to help in the prevention and treatment of PAD in an effort to combat the affects of this disease.
Learn more about TV1001SR and PAD
family

Theravasc in the News

Over the past several years, Theravasc has appeared in the news multiple times as we continue to work on the development of our new drug, TV1001SR. See press releases and news articles about us and the development of our new drug.
See Press Releases & News Articles

Dr. Amol Soin Is Interviewed About Our New Diabetic Pain Drug On Local Dayton TV

home-icon-newsRECENT NEWS

Hillsboro doctor develops new experimental diabetic neuropathy treatment

Highland County Press Dr. Amol Soin, Medical Director of the Ohio Pain Clinic, with an office in Hillsboro, has announced the development of a treatment for diabetic neuropathy pain. Dr. Soin and his team filed a patent last February for an investigational, non-addicting/sedating pill and filed an Investigational New Drug Application with the FDA in December 2014, paving the way for clinical tests to be done locally starting within a few months. A co-inventor of this medication, Dr. Soin points out that over 300 million people worldwide suffer from diabetes, and this number is expected to grow by over 50 percent by 2035. News reports note that the diabetes epidemic shows no signs of slowing in the United States and around the world. This new pill features enteric-coated, time-released sodium nitrite, which stimulates blood vessel growth and has been shown in a previous study to significantly reduce pain in patients suffering from diabetic neuropathy without being addicting or sedating. With the rise of drug abuse and addiction in patients who take narcotics for relief of their symptoms, having an option to treat neuropathy with a new modality could potentially change the entire paradigm for pain treatment. By stimulating blood vessel growth in diabetics, the drug has added advantages of helping increase blood flow to the feet which may aid in wound healing, diabetic foot ulcer prevention and may prevent damage/limb loss which often occurs in diabetics by improving circulation. It has been described as “a novel therapeutic approach,” and preliminary testing has been very encouraging and has highlighted the potent effect and benefits of nitrite therapy. The upcoming trial...

Dayton-area entrepreneur on cusp of ‘billion-dollar’ product (Exclusive)

by Tristan Navera Dayton Business Journal – Febuary 4, 2015 Dr. Amol Soin is setting his sights on a new drug with immense potential for pain relief. It also has huge potential for helping to create the next billion-dollar company in the Dayton region. Soin, who is head of Centerville-based Ohio Pain Clinic, is part of a team of physicians developing a drug that treats diabetic neuropathy pain. Soin and his team filed a patent last February and filed an Investigational New Drug Application with the U.S. Food and Drug Administration in December, paving the way for clinical tests to be done locally starting within a few months. If the results continue to be encouraging, the drug could be introduced on a national scale. And it could have a major effect. About 300 million people worldwide suffer from diabetes, a number expected to grow to 450 million by 2035. “It’s got the potential to be a $1 billion-a-year drug,” Soin said, noting major national drugs intended to treat pain, like Lipitor and Lyrica, exceed $1.5 billion a year in sales. The drug Soin co-invented features enteric coated, time-released sodium nitrite, which is intended to stimulate blood vessel growth and has been shown in early tests to reduce pain in patients with diabetic neuropathy, but it is not a narcotic or a sedative. “A non-narcotic, non-sedative, non-addicting drug to treat pain – really could be the holy grail,” Soin said. “I think this will be a real game-changer. For far too long we have been treating pain with addicting narcotics and finally we will have an option that treats the...